公开(公告)号：US20220241284A1

公开(公告)日：2022-08-04

申请号：US17610787

申请日：2020-05-14

Applicant: LEO PHARMA A/S

Inventor： Jacob NIELSEN ,  Gitte Pommergaard PEDERSEN ,  Helene MORTENSEN ,  Camilla SANDER ,  Pia Klie REFER

IPC: A61K31/519 ,  A61K9/00 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K9/10

Abstract: The present invention relates to the treatment of cutaneous lupus erythematosus. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, a therapeutic or preventive agent cutaneous lupus erythematosus, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient, and a pharmaceutical formulation thereof.